The pattern of pro- and anti-inflammatory cytokine secretion in patients with secondary edematous breast cancer

Authors

DOI:

https://doi.org/10.14739/2310-1210.2021.4.214070

Keywords:

breast cancer, disease progression, cytokines

Abstract

Secondary edematous breast cancer (SEBC), T4b, has a poor prognosis.

The aim of this study is to examine the balance in serum levels of pro-inflammatory (TNFά, IL-8) and anti-inflammatory (IL-4) cytokines in patients with SEBC before special treatment.

Materials and methods. A total of 87 patients with breast cancer (BC) were examined before treatment: 42 patients with SEBC in T4bN0-3M0 stage and 45 BC patients in T3-4N1-3M0 stage without edema. The control group consisted of 15 patients with fibroadenomas. The serum levels of cytokines (IL-4, IL-8, TNFά) in the patients was determined using the enzyme-linked immunosorbent assay.

Results. In the SEBC patients as compared to the patients without cancer, the serum pro-inflammatory cytokine (IL-8, TNFά) levels were significantly increased and the anti-inflammatory cytokine (IL-4) level was slightly increased in 22 %. In BC without edema, an imbalance was noted in favor of pro-inflammatory cytokines, but in SEBC it was more pronounced (31.6 versus 12.4 and 5.6 versus 3.2, respectively).

Conclusions. In the majority of SEBC patients, there is an imbalance in the cytokine profile in favor of the pro-inflammatory cytokines (IL-8, TNFά). SEBC patients with elevated levels of both pro- and anti-inflammatory cytokines before treatment are the highest risk group of tumor progression and metastasis. Inhibition of the IL-8 effects or related CXC chemokines, TNFά, and others may have important consequences for the systemic treatment of SEBC.

Author Biographies

O. M. Bilyi, V. N. Karazin Kharkiv National University, Ukraine

MD, PhD, Senior Researcher of the Department of Surgical Oncology, State Institution “Institute of Medical Radiology and Oncology named after S. P. Grigoriev of the National Academy of Medical Sciences of Ukraine”; Associate Professor of the Department of Oncology, Radiology and Radiation Medicine

N. A. Mitriaieva, State Institution “Institute of Medical Radiology and Oncology named after S.P. Grigoriev of the National Academy of Medical Sciences of Ukraine”, Kharkiv

PhD, DSc, Senior Researcher, Head of the Laboratory of Radiation Oncology

M. V. Krasnoselskyi, V. N. Karazin Kharkiv National University, Ukraine

MD, PhD, DSc, Professor, Director of the State Institution “Institute of Medical Radiology and Oncology named after S. P. Grigoriev of the National Academy of Medical Sciences of Ukraine”; Head of the Department of Oncology, Radiology and Radiation Medicine

L. V. Hrebinyk, State Institution “Institute of Medical Radiology and Oncology named after S. P. Grigoriev of the National Academy of Medical Sciences of Ukraine”, Kharkiv

Researcher, Laboratory of Radiation Oncology

References

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30. https://doi.org/10.3322/caac.21590

Romanoff, A., Zabor, E. C., Petruolo, O., Stempel, M., El-Tamer, M., Morrow, M. & Barrio, A. V. (2018). Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? Cancer, 124(22), 4314-4321. https://doi.org/10.1002/cncr.31757

Gentile, L. F., Plitas, G., Zabor, E. C., Stempel, M., Morrow, M., & Barrio, A. V. (2017). Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. Annals of Surgical Oncology, 24(13), 3896-3902. https://doi.org/10.1245/s10434-017-6085-y

Singh, N., Baby, D., Rajguru, J. P., Patil, P. B., Thakkannavar, S. S., & Pujari, V. B. (2019). Inflammation and Cancer. Annals of African Medicine, 18(3), 121-126. https://doi.org/10.4103/aam.aam_56_18

King, J., Mir, H., & Singh, S. (2017). Chapter Four - Association of Cytokines and Chemokines in Pathogenesis of Breast Cancer. In R. Lakshmanaswamy (Ed.), Progress in Molecular Biology and Translational Science (Vol. 151, pp. 113-136). Academic Press. https://doi.org/10.1016/bs.pmbts.2017.07.003

Ma, Y., Ren, Y., Dai, Z.-J., Wu, C.-J., Ji, Y.-H., & Xu, J. (2017). IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients. Advances in Clinical and Experimental Medicine, 26(3), 421-426. https://doi.org/10.17219/acem/62120

Cruceriu, D., Baldasici, O., Balacescu, O., & Berindan-Neagoe, I. (2020). The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cellular Oncology, 43(1), 1-18. https://doi.org/10.1007/s13402-019-00489-1

Agnoli, C., Grioni, S., Pala, V., Allione, A., Matullo, G., Gaetano, C. D., Tagliabue, G., Sieri, S., & Krogh, V. (2017). Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort. Scientific Reports, 7(1), Article 12708. https://doi.org/10.1038/s41598-017-12703-x

Annibaldi, A., & Meier, P. (2018). Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer. Trends in Molecular Medicine, 24(1), 49-65. https://doi.org/10.1016/j.molmed.2017.11.002

Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016). The CXCL8-CXCR1/2 pathways in cancer. Cytokine & Growth Factor Reviews, 31, 61-71. https://doi.org/10.1016/j.cytogfr.2016.08.002

Tiainen, L., Hämäläinen, M., Luukkaala, T., Tanner, M., Lahdenperä, O., Vihinen, P., Jukkola, A., & Kellokumpu-Lehtinen, P. L. (2019). Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 19(4), e522-e533. https://doi.org/10.1016/j.clbc.2019.03.006

Ortiz-Montero, P., Londoño-Vallejo, A., & Vernot, J. P. (2017). Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Communication and Signaling, 15(1), Article 17. https://doi.org/10.1186/s12964-017-0172-3

Kawaguchi, K., Sakurai, M., Yamamoto, Y., Suzuki, E., Tsuda, M., Kataoka, T. R., Hirata, M., Nishie, M., Nojiri, T., Kumazoe, M., Saito, K., & Toi, M. (2019). Alteration of specific cytokine expression patterns in patients with breast cancer. Scientific Reports, 9(1), Article 2924. https://doi.org/10.1038/s41598-019-39476-9

Tower, H., Ruppert, M., & Britt, K. (2019). The Immune Microenvironment of Breast Cancer Progression. Cancers, 11(9), Article 1375. https://doi.org/10.3390/cancers11091375

Liu, D., Wang, X., & Chen, Z. (2016). Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer. Current Pharmaceutical Biotechnology, 17(6), 486-494. https://doi.org/10.2174/1389201017666160301102713

Published

2021-07-01

How to Cite

1.
Bilyi OM, Mitriaieva NA, Krasnoselskyi MV, Hrebinyk LV. The pattern of pro- and anti-inflammatory cytokine secretion in patients with secondary edematous breast cancer. Zaporozhye Medical Journal [Internet]. 2021Jul.1 [cited 2024Jul.20];23(4):536-40. Available from: http://zmj.zsmu.edu.ua/article/view/214070

Issue

Section

Original research